NASDAQ:VERA Vera Therapeutics Q1 2025 Earnings Report $32.04 -0.24 (-0.75%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vera Therapeutics EPS ResultsActual EPS-$0.81Consensus EPS -$0.75Beat/MissMissed by -$0.06One Year Ago EPS-$0.56Vera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVera Therapeutics Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateTuesday, May 6, 2025Conference Call Time8:00AM ETUpcoming EarningsVera Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vera Therapeutics Earnings HeadlinesJ.P. Morgan Sticks to Their Buy Rating for Vera Therapeutics (VERA)3 hours ago | theglobeandmail.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Moderate Buy" by AnalystsAugust 19 at 2:28 AM | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.August 19 at 1:00 AM | Profits Run (Ad)Vera Therapeutics (NASDAQ:VERA) Earns "Neutral" Rating from WedbushAugust 19 at 1:48 AM | americanbankingnews.comVera Therapeutics: FDA's eGFR Analysis Supports A Speculative BuyAugust 17 at 3:00 PM | seekingalpha.comQ3 EPS Forecast for Vera Therapeutics Boosted by AnalystAugust 16 at 1:13 AM | americanbankingnews.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs. The company concentrates on high-unmet-need autoimmune disorders, pursuing therapies that can broadly benefit patient populations worldwide. Through strategic partnerships and disciplined clinical execution, Vera Therapeutics seeks to accelerate the translation of its immunomodulatory candidates. The leadership team at Vera Therapeutics brings extensive experience in biologics development, translational research and regulatory affairs, supported by an accomplished scientific advisory board. As a NASDAQ‐listed company trading under the ticker VERA, it is well positioned to drive its innovative platform toward key clinical milestones and deliver new treatment options for immune-mediated diseases.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Quantum Stocks Are Starting to Choose Sides: Should Investors Do the Same?AeroVironment Hit a Bottom in Q2—Can It Take Flight in Q3?Tesla's Cybercab Launch Could Reshape Margins for Uber and LyftPony AI Stock Gains Traction as Robotaxi Fleet Expands GloballySpeed Sells: Cerebras Cracks the Silicon CeilingHome Depot Analysts See a Path to $375 and BeyondRTX Stock Gets a Radar Lock on a $23B Navy Win Upcoming Earnings NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Heico (8/25/2026)Intuit (8/25/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
